Ultragenyx Pharmaceutical（纳斯达克代码：RARE）宣布，其创新疗法DTx301在治疗周期第36周时展现出显著疗效——患者24小时血浆氨水平较安慰剂组平均降低18%。该数据来自针对尿素循环障碍患者的二期临床试验，证实了DTx301在持续控制血氨方面的临床价值。
Ultragenyx Pharmaceutical（纳斯达克代码：RARE）宣布，其创新疗法DTx301在治疗周期第36周时展现出显著疗效——患者24小时血浆氨水平较安慰剂组平均降低18%。该数据来自针对尿素循环障碍患者的二期临床试验，证实了DTx301在持续控制血氨方面的临床价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.